Skip to main content
OpenTrials
Completed

NCT Number: NCT04866576

Effect of a Fermented Soy Product on Cognition, Immune Status and Vaccine

The research study will test the effects of Q CAN PLUS powder on the immune, inflammatory and cognitive functions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Loma Linda University School of Public Health

Loma Linda, California, 92350, United States

About this study

The purpose of this study is to determine the effects of a fermented soy product (Q-CAN), compared to placebo, on the immune, inflammatory and cognitive functions of elderly individuals. The study intervention will be four months in length. sixty two participants , 65 years or older will be randomized to participate in the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Elderly men and women, 65 years of age or older
  • Ambulatory
  • Able to accommodate the intervention food products
  • Live in or around Loma Linda to be able to commute to the Nutrition Research Center

Exclusion criteria

  • Intolerance to soy products
  • Immune system insufficiency or disease
  • Insulin dependent diabetes mellitus
  • Alzheimer's disease
  • Dialysis
  • Current cancer radiation or chemotherapy
  • Prednisone or Prednisolone Therapy greater than 10mg/d

Treatment and study plan

Q CAN PLUS

Dietary Supplement

Active powder with fermented soy, 2 pouches per day, each pouch contains 12-15 gms of fermented soy

Placebo

Dietary Supplement

Maltodextrin powder with Whey protein and flavor (provided by BESO Biological Research, Inc.)

Primary outcomes

  1. Changes in immune status measurements

    Time frame: baseline to week 16

    Immune status measurements will be performed using both static and functional tests on whole blood, serum and peripheral blood mononuclear cells (PBMC). Phlebotomy to obtain the needed samples will be performed at baseline (week 0) and at 16 weeks. Changes in immune status include changes in: (a) lymphocyte activity and cytokine production (b) natural killer cells activity, (c) lymphocyte subsets, and (d) inflammatory markers and cytokines.

  2. Changes in lymphocyte activity and cytokine production

    Time frame: baseline to week 16

    Lymphocyte activity and cytokine production will be measured using enzyme-linked immunoassay (ELISA) and flow cytometry. Peripheral blood mononuclear cells (PBMCs) will be incubated and stimulated with or without phytohemagglutinin (PHA) or Lipopolysaccharide (LPS) and the culture supernatant fluids collected and assayed using ELISA for the following cytokines: granulocyte macrophage colony- stimulating Factor (GM-CSF), tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), interleukin 1 beta (IL-1β), interleukin 2 (IL-2), interleukin 6 (IL-6), and interleukin 10 (IL-10).

  3. Changes in lymphocyte subsets

    Time frame: baseline to week 16

    Immunophenotyping will be performed on cryopreserved PBMCs using a flow cytometry. The following markers will be measured: T cytotoxic cells (Tc; CD3+CD8+), T helper cells (Th; CD3+CD4+), B cells (CD19+), NK cells (NK; CD3-CD16+), and regulatory T cells (Treg; CD3+CD4+CD25+Foxp3+).

  4. Changes in inflammatory factors and cytokines

    Time frame: baseline to week 16

    Inflammatory markers in serum will be measured by ELISA and will include C-reactive protein (CRP), E-selectin, Pentraxin 3, Rantes, MCP-1 and Eotaxin.

    Immunophenotyping will be performed on cryopreserved PBMCs using a flow cytometry. The following markers will be measured: T cytotoxic cells (Tc; CD3+CD8+), T helper cells (Th; CD3+CD4+), B cells (CD19+), NK cells (NK; CD3-CD16+), and regulatory T cells (Treg; CD3+CD4+CD25+Foxp3+). Additional characterization of T cells based on naive and memory phenotypes will be determined by corresponding patterns in the expression of CD45RA, CD45RO and CD62L, while different subpopulations of Tregs will be further differentiated by expressions of GITR, CTLA-4 and LAG-3

  5. Changes in complete blood count (CBC) and differential count

    Time frame: baseline to week 16

    CBC and the differential counts will be performed on whole blood with the use of an automated hematology analyzer at a certified clinical facility.

    Immunophenotyping will be performed on cryopreserved PBMCs using a flow cytometry. The following markers will be measured: T cytotoxic cells (Tc; CD3+CD8+), T helper cells (Th; CD3+CD4+), B cells (CD19+), NK cells (NK; CD3-CD16+), and regulatory T cells (Treg; CD3+CD4+CD25+Foxp3+). Additional characterization of T cells based on naive and memory phenotypes will be determined by corresponding patterns in the expression of CD45RA, CD45RO and CD62L, while different subpopulations of Tregs will be further differentiated by expressions of GITR, CTLA-4 and LAG-3

Secondary outcomes

  1. Changes from baseline in global cognitive composite score

    Time frame: baseline to week 16

    The composite score will be calculated using the scores from the tests listed below. We will calculate the standardized scores of each test as the score of each participant minus the group mean and divide by its standard deviation. The composite score is the mean of the standardized scores.

    The 12 tests are: Rey Auditory Verbal Learning Test (RAVLT), Rey-Osterrieth Complex Figure (ROCF), Semantic Fluency (Animals), Boston Naming Test (BNT), Visual Object and Space Perception Battery (VOSP), Block Design section from the Wechsler Adult Intelligence Scale (WAIS-III), Trail Making Test (TMT), FAS Word Fluency, Stroop Color Word Test, Symbol Digit Modalities Test (SMDT) Digit Span from the WAIS-III and Conners Continuous Performance Test (CPT-II).

  2. Changes in the upper respiratory infection questionnaire score

    Time frame: baseline to week 16

    Upper respiratory tract infections will be tracked using the Jackson and Dowling questionnaire as adapted and published by Martineau et al. (2015). The questionnaire will be completed daily by participants, either manually or electronically, throughout the 20-week study period

Sponsors and collaborators

Lead sponsor

Loma Linda University

Other

Registry information

Official study title

Effect of a Fermented Soy Product on Cognition, Immune Status and Response to Influenza Vaccine in Elderly Men and Women

Acronym: IS

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Apr 30, 2021
Registry last updated
Dec 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.